Login
$CTMX
$2.02 +$0.03 (1.76%) After hours

$CTMX 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer -

06 Aug 2026 8-K: Results of Operations and Financial Condition

- Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 -

27 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

22 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

1.1 Purposes. This CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan, as amended by the Board on March 18, 2026 (this “Plan”), is effective as of the date the stockholders of the Company approve this Plan. The pur...

03 Jun 2026 8-K: Entry into a Material Definitive Agreement

CytomX Therapeutics, Inc. (the “Company”) previously entered into that certain Collaboration and License Agreement, effective November 16, 2022 (as amended, the “Agreement”), with Regeneron Pharmaceuticals, Inc. (“Regeneron”), providing ...

07 May 2026 8-K: Results of Operations and Financial Condition

- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) -

19 Mar 2026 8-K: Other Events

Pre-Funded Warrants to Purchase 1,179,245 shares of Common Stock

16 Mar 2026 8-K: Results of Operations and Financial Condition

- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) -

06 Nov 2025 8-K: Results of Operations and Financial Condition

- CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 -

13 Aug 2025 8-K: Other Events

On August 13, 2025, CytomX Therapeutics, Inc. (the “Company”) announced an update on the CX-2051 Phase 1 study. The CX-2051 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses, administered every three weeks, have each enrolled a...

07 Aug 2025 8-K: Results of Operations and Financial Condition

- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -

13 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

1.1 Purposes. This CytomX Therapeutics, Inc. Amended and Restated 2015 Equity Incentive Plan as set forth herein (this “Plan”) amends, restates and supersedes the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan effective as of the d...

28 May 2025 8-K: Other Events

As previously reported, on February 24, 2025, CytomX Therapeutics, Inc. (the “Company”) was notified by the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) that its common stock, par val...

13 May 2025 8-K: Other Events

As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto

12 May 2025 8-K: Results of Operations and Financial Condition; Other Events

- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM

06 Mar 2025 8-K: Results of Operations and Financial Condition

- Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 -

26 Feb 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

03 Feb 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

06 Jan 2025 8-K: Costs Associated with Exit or Disposal Activities

On January 6, 2025, CytomX Therapeutics, Inc. (the “Company”) announced plans to restructure its business to streamline its organization and prioritize CX-2051 (EpCAM PROBODY® ADC) and its activities to support its research collaboration...

07 Nov 2024 8-K: Results of Operations and Financial Condition

- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support